Alanine transaminase has opposite associations with death from diabetes and ischemic heart disease in NHANES III

Annals of Epidemiology

Volumn 22, Issue 11, 2012, Pages 789-798

  Schooling, C Mary ^a   Kelvin, Elizabeth A ^a   Jones, Heidi E ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Alanine transaminase; Cardiovascular disease; Cohort; Diabetes; Global; Liver function; Mortality

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN;

ADULT; ALCOHOL ABUSE; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FEMALE; GENETIC LINKAGE; HEALTH SURVEY; HUMAN; ISCHEMIC HEART DISEASE; LIVER CELL DAMAGE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SMOKING;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; CAUSE OF DEATH; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; INTERVIEWS AS TOPIC; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; NUTRITION SURVEYS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; SMOKING; UNITED STATES; YOUNG ADULT;

EID: 84868206437     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2012.08.003     Document Type: Article

References (57)

1. He J., Gu D., Wu X., Duan X., Yao C., Wang J., et al. Major causes of death among men and women in China. N Engl J Med 2005, 353:1124-1134.
2. Yang W., Lu J., Weng J., Jia W., Ji L., Xiao J., et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010, 362:1090-1101.
3. Iribarren C., Darbinian J.A., Fireman B.H., Burchard E.G. Birthplace and mortality among insured Latinos: the paradox revisited. Ethn Dis 2009, 19:185-191.
4. Cowie C.C., Rust K.F., Ford E.S., Eberhardt M.S., Byrd-Holt D.D., Li C., et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009, 32:287-294.
5. Stirbu I., Kunst A.E., Bos V., Mackenbach J.P. Differences in avoidable mortality between migrants and the native Dutch in The Netherlands. BMC Public Health 2006, 6:78. 78.
6. Agyemang C., Addo J., Bhopal R., de Graft A.A., Stronks K. Cardiovascular disease, diabetes and established risk factors among populations of sub-Saharan African descent in Europe: a literature review. Global Health 2009, 5:7. 7.
7. Medalie J.H. Risk factors other than hyperglycemia in diabetic macrovascular disease. Diabetes Care 1979, 2:77-84.
8. Sarwar N., Gao P., Seshasai S.R., Gobin R., Kaptoge S., Di Angelantonio E., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222. Emerging Risk Factors Collaboration.
9. Boussageon R., Bejan-Angoulvant T., Saadatian-Elahi M., Lafont S., Bergeonneau C., Kassaï B., et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011, 343:d4169.
10. Mills E.J., Wu P., Chong G., Ghement I., Singh S., Akl E.A., et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011, 104:109-124.
11. Gueyffier F., Boutitie F., Boissel J.P., Pocock S., Coope J., Cutler J., et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997, 126:761-767.
12. Anjana R.M., Pradeepa R., Deepa M., Datta M., Sudha V., Unnikrishnan R., et al. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: Phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. Diabetologia 2011, 54:3022-3027.
13. Mihardja L., Delima, Manz H.S., Ghani L., Soegondo S. Prevalence and determinants of diabetes mellitus and impaired glucose tolerance in Indonesia (a part of basic health research/Riskesdas). Acta Med Indones 2009, 41:169-174.
14. Hall V., Thomsen R.W., Henriksen O., Lohse N. Diabetes in Sub Saharan Africa 1999-2011: epidemiology and public health implications. A systematic review. BMC Public Health 2011, 11:564.
15. Fraser A., Harris R., Sattar N., Ebrahim S., Davey Smith G., Lawlor D.A. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009, 32:741-750.
16. Fraser A., Harris R., Sattar N., Ebrahim S., Smith G.D., Lawlor D.A. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007, 27:2729-2735.
17. Goessling W., Massaro J.M., Vasan R.S., D'Agostino R.B., Ellison R.C., Fox C.S. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008, 135:1935-1944.
18. Olynyk J.K., Knuiman M.W., Divitini M.L., Davis T.M., Beilby J., Hung J. Serum alanine aminotransferase, metabolic syndrome, and cardiovascular disease in an Australian population. Am J Gastroenterol 2009, 104:1715-1722.
19. Ruhl C.E., Everhart J.E. Non-alcoholic fatty liver disease (NAFLD) and mortality. J Hepatol 2009, 51:593-595.
20. Schindhelm R.K., Dekker J.M., Nijpels G., Bouter L.M., Stehouwer C.D., Heine R.J., et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007, 191:391-396.
21. Ford I., Mooijaart S.P., Lloyd S., Murray H.M., Westendorp R.G., de Craen A.J., et al. The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. Int J Epidemiol 2011, 40:1530-1538.
22. Green R.M., Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002, 123:1367-1384.
23. Musana K.A., Yale S.H., Abdulkarim A.S. Tests of liver injury. Clin Med Res 2004, 2:129-131.
24. Schooling C.M., Jiang C.Q., Zhang W.S., Lam T.H., Cheng K.K., Leung G.M. Visceral adiposity would be expected to predict incident diabetes better in women than men. Diabetologia 2010, 53:393-395.
25. Schooling C.M., Jiang C.Q., Zhang W.S., Lam T.H., Cheng K.K., Leung G.M. Adolescent build and diabetes: the Guangzhou Biobank Cohort Study. Ann Epidemiol 2011, 21:61-66.
26. Schooling C.M., Hui L.L., Ho L.M., Lam T.H., Leung G.M. Cohort profile: 'Children of 1997': a Hong Kong Chinese birth cohort. Int J Epidemiol 2011, 41:611-620.
27. Hu Y.W., Zheng L., Wang Q. Regulation of cholesterol homeostasis by liver X receptors. Clin Chim Acta 2010, 411:617-625.
28. Jin Y., Penning T.M. Steroid 5alpha-reductases and 3alpha-hydroxysteroid dehydrogenases: key enzymes in androgen metabolism. Best Pract Res Clin Endocrinol Metab 2001, 15:79-94.
29. Stamoulis I., Kouraklis G., Theocharis S. Zinc and the liver: an active interaction. Dig Dis Sci 2007, 52:1595-1612.
30. Ebisch I.M., Thomas C.M., Peters W.H., Braat D.D., Steegers-Theunissen R.P. The importance of folate, zinc and antioxidants in the pathogenesis and prevention of subfertility. Hum Reprod Update 2007, 13:163-174.
31. Foresta C., Schipilliti M., Ciarleglio F.A., Lenzi A., D'Amico D. Male hypogonadism in cirrhosis and after liver transplantation. J Endocrinol Invest 2008, 31:470-478.
32. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
33. U.S. Centers for Disease Control and Prevention. National Health and Nutrition Examination survey,; 2011. Ref Type: Online Source. http://www.cdc.gov/nchs/nhanes/nh3data.htm.
34. Piton A., Poynard T., Imbert-Bismut F., Khalil L., Delattre J., Pelissier E., et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 1998, 27:1213-1219.
35. Prati D., Taioli E., Zanella A., Della Torre E., Butelli S., Del Vecchio E., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002, 137:1-10.
36. Kariv R., Leshno M., Beth-Or A., Strul H., Blendis L., Kokia E., et al. Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. Liver Int 2006, 26:445-450.
37. Sun X., Briel M., Walter S.D., Guyatt G.H. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010, 340:c117. c117. 10.1136/bmj.c117.
38. Andersen P.K., Abildstrom S.Z., Rosthoj S. Competing risks as a multi-state model. Stat Methods Med Res 2002, 11:203-215.
39. Satagopan J.M., Ben-Porat L., Berwick M., Robson M., Kutler D., Auerbach A.D. A note on competing risks in survival data analysis. Br J Cancer 2004, 91:1229-1235.
40. Yun K.E., Shin C.Y., Yoon Y.S., Park H.S. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 2009, 205:533-537.
41. Marchesini G., Targher G. Commentary: liver enzymes and the risk of adverse cardiovascular outcomes-the lower, the better?. Int J Epidemiol 2011, 40:1539-1541.
42. Flores Y.N., Yee H.F., Leng M., Escarce J.J., Bastani R., Salmerón J., et al. Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004. Am J Gastroenterol 2008, 103:2231-2238.
43. Zhang H., He S.M., Sun J., Wang C., Jiang Y.F., Gu Q., et al. Prevalence and etiology of abnormal liver tests in an adult population in Jilin, China. Int J Med Sci 2011, 8:254-262.
44. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
45. Sim H.G., Cheng C.W. Changing demography of prostate cancer in Asia. Eur J Cancer 2005, 41:834-845.
46. Wickramasinghe S.N., Corridan B., Izaguirre J., Hasan R., Marjot D.H. Ethnic differences in the biological consequences of alcohol abuse: a comparison between south Asian and European males. Alcohol Alcohol 1995, 30:675-680.
47. Misra A., Ganda O.P. Migration and its impact on adiposity and type 2 diabetes. Nutrition 2007, 23:696-708.
48. Bhopal R.S., Rafnsson S.B., Agyemang C., Fagot-Campagna A., Giampaoli S., Hammar N., et al. Mortality from circulatory diseases by specific country of birth across six European countries: test of concept. Eur J Public Health 2011, 22:353-359.
49. Palaniappan L., Wang Y., Fortmann S.P. Coronary heart disease mortality for six ethnic groups in California, 1990-2000. Ann Epidemiol 2004, 14:499-506.
50. Gray L., Harding S., Reid A. Evidence of divergence with duration of residence in circulatory disease mortality in migrants to Australia. Eur J Public Health 2007, 17:550-554.
51. Shin H.R., Joubert C., Boniol M., Hery C., Ahn S.H., Won Y.J., et al. Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women. Cancer Causes Control 2010, 21:1777-1785.
52. Trapido E.J., Burciaga V.R., Obeso J.L., Strickman-Stein N., Rotger A., Pérez-Stable E.J. Epidemiology of cancer among Hispanics in the United States. J Natl Cancer Inst Monogr 1995, 17-28.
53. Mangtani P., Maringe C., Rachet B., Coleman M.P., dos Santos Silva I. Cancer mortality in ethnic South Asian migrants in England and Wales (1993-2003): patterns in the overall population and in first and subsequent generations. Br J Cancer 2010, 102:1438-1443.
54. Lawlor D.A., Harbord R.M., Sterne J.A., Timpson N., Davey S.G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008, 27:1133-1163.
55. Hotta K., Yoneda M., Hyogo H., Ochi H., Mizusawa S., Ueno T., et al. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet 2010, 11:172.
56. Stickel F., Buch S., Lau K., Meyer zu Schwabedissen H., Berg T., Ridinger M., et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in Caucasians. Hepatology 2011, 53:86-95.
57. Speliotes E.K., Yerges-Armstrong L.M., Wu J., Hernaez R., Kim L.J., Palmer C.D., et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011, 7:e1001324.